Securities & Capital Markets

Mintz advised the underwriters in connection with a $603 million public offering by Praxis Precision Medicines of 3,527,072 shares of common stock (which includes 501,592 shares of common stock.

Mintz advised the placement agents in connection with Spruce Biosciences, Inc.'s $50 million private placement. The investors purchased common stock (and pre-funded warrants in lieu of common stock for certain investors).

Mintz Advises on uniQure's $345 Million Public Offering

Mintz advised the underwriters in LB Pharmaceuticals’ $285 million IPO of 19 million shares on Nasdaq under the ticker 'LBRX'. Leerink Partners, Piper Sandler, and Stifel served as joint bookrunners.

Mintz represented the underwriters in Ondas Holdings Inc.’s $230 million public offering of 46 million shares. Oppenheimer led the deal, with support from Stifel and other co-managers.

Mintz advised ArriVent BioPharma, Inc. on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock.

Mintz represented Oppenheimer & Co., as sole book-running manager, and Craig-Hallum Capital Group and Northland Securities, as co-managers, in the private placement of $475 million aggregate principal amount of 4.625% Convertible Senior Notes due 2030 issued by WisdomTree, Inc (NYSE: WT) (“WisdomTree”).

Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.

Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock.

Mintz advised the lead placement agent in connection with an up to $50 million private placement by Equillium, Inc.

Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.

Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share.

Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share.

Mintz advised client ArriVent BioPharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, on its upsized $175 million IPO on Nasdaq.

When Daré Bioscience Operations, Inc. first became a Mintz client, it was a private health care company working to develop innovative product candidates in women’s reproductive health. Due to the significant expenses associated with product development and regulatory compliance for innovative drug, device, and combination products, the San Diego-based company sought to raise capital through entering the public markets. Since becoming a public company, Daré Bioscience has in-licensed multiple exciting product candidates focused on women’s sexual health, vaginal health, fertility, and contraception and prioritized a goal of achieving FDA marketing approval for one or more products.

The Mintz team accomplished this negotiation through its long-standing relationship with Aspen, which dates back to 2010, and its comprehensive understanding of the company’s goals. Mintz represented Aspen during its initial public offering (IPO) as well as through numerous additional financings and strategic partnerships targeting new product and market opportunities.

Mintz is advising Vicarious Surgical Inc., a robotics company developing technology that combines human-like surgical robots and virtual reality to perform minimally invasive surgery, in a pending merger with special purpose acquisition company D8 Holdings Corp. that is expected to deliver up to $460 million in gross proceeds.

Mintz is advising DeepGreen Metals Inc., a company developing a new source of electric vehicle battery metals from polymetallic nodules found on the seafloor, in its proposed merger with Sustainable Opportunities Acquisition Corporation, a special purpose acquisition company (SPAC) focused on ESG.

Mintz analyzed PitchBook data to produce an in-depth report on the record rise in special purpose acquisition company (SPAC) fundraising in the US since 2020 and the recent increase in SPAC merger activity. We also explore how SPACs could evolve and litigation challenges to SPAC IPOs and transactions.

Mintz is acting as legal advisor to Quantum-SI Incorporated, developer of a pioneering semiconductor chip to sequence proteins, in its proposed business combination with HighCape Capital Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by growth equity investment firm HighCape Capital LP.

Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.

After a lender abandoned our client’s financing transaction over concerns related to COVID-19, Mintz negotiated a convertible note financing with another investor — providing the client with up to $25M to pursue commercialization of its lead product.

Mintz advised Oberon Fuels, a developer of an ultra-low-carbon fuel known as renewable dimethyl ether (rDME), on a strategic collaboration with propane fuel distributor SHV Energy. The agreement will help Oberon scale up its pilot facility to produce the first rDME fuel in the United States.

After helping Spero raise over $200 million, Mintz represented the biopharmaceutical company in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb).

In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.

Mintz steered precision health company Quanterix Corporation through a $73.7 million initial public offering (IPO). The firm’s Securities & Capital Markets Practice advised Quanterix on the Securities and Exchange Commission review process as well as pricing and timing of the offering.

Mintz helped women’s reproductive health care company Daré Bioscience Operations, Inc. become a wholly owned subsidiary of Cerulean and a publicly traded company named Daré Bioscience, Inc. The innovative deal utilized a variation of a reverse merger into a publicly traded fallen-angel.

Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.